OncoCyte (NAS:OCX) Dividend Yield %

: 0.00% (As of Today)

View and export this data going back to 2015. Start your Free Trial

As of today (2023-01-30), the Trailing Annual Dividend Yield of OncoCyte is 0.00%.

The historical rank and industry rank for OncoCyte's Dividend Yield % or its related term are showing as below:

OncoCyte's Dividend Payout Ratio for the three months ended in Sep. 2022 was 0.00.

As of today (2023-01-30), the Forward Dividend Yield % of OncoCyte is 0.00%.

OncoCyte's Dividends per Share for the three months ended in Sep. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

OncoCyte Dividend Yield % Historical Data

The historical data trend for OncoCyte's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dividend Yield %

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Dividend Yield %																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

OncoCyte Dividend Yield % Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where OncoCyte's Dividend Yield % falls in comparison to its industry or sector. The grey bar indicates the Dividend Yield %'s extreme value range as defined by GuruFocus.

OncoCyte Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

OncoCyte (NAS:OCX) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

OncoCyte Dividend Yield % Related Terms

Thank you for viewing the detailed overview of OncoCyte's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Dividend Yield %

Comparable Companies

Traded in Other Exchanges

0KCC:UK 7OC:Germany 7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Paulsen Gisela	officer: Chief Operating Officer	5505 ENDEAVOR LANE MADISON WI 53719
Yu Li	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L.	director	C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T.	officer: Chief Medical Officer	15 CUSHING IRVINE CA 92618
Kamen Efrem	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda	director	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury	director	5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P	officer: Chief Operating Officer	C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S	officer: Chief Financial Officer	ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K.	officer: Sr VP, Research & Development	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M	director	1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C	10 percent owner